Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 11-12, 2016, Pages 1235-1241

  Economides, M P ^a   Mahale, P ^a   Kyvernitakis, A ^a   Turturro, F ^a   Kantarjian, H ^a   Naing, A ^a   Hosry, J ^a   Shigle, T L ^a   Kaseb, A ^a   Torres, H A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENDAMUSTINE; BEVACIZUMAB; BORTEZOMIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLATASVIR; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; IRINOTECAN; LEDIPASVIR; LENALIDOMIDE; OBINUTUZUMAB; OXALIPLATIN; PERTUZUMAB; RIBAVIRIN; RITUXIMAB; SIMEPREVIR; SOFOSBUVIR; SORAFENIB; TACROLIMUS; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VIRUS RNA;

ABDOMINAL PAIN; ACUTE MYELOBLASTIC LEUKEMIA; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOATING; BLURRED VISION; BREAST CANCER; CANCER CHEMOTHERAPY; CHRONIC HEPATITIS C; CLINICAL ARTICLE; COLON CANCER; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DRUG RESPONSE; DRUG SAFETY; DYSPHAGIA; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; HEADACHE; HEARING IMPAIRMENT; HEMATOLOGIC MALIGNANCY; HUMAN; INSOMNIA; LARGE CELL LYMPHOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MONITORING; MULTIPLE MYELOMA; MYALGIA; MYCOSIS FUNGOIDES; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OBSERVATIONAL STUDY; ODYNOPHAGIA; PANIC; PARESTHESIA; PHARYNX CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RECTUM HEMORRHAGE; SIDE EFFECT; SKIN TINGLING; THROMBOCYTOPENIA; VIROLOGY; VOMITING; WALDENSTROEM MACROGLOBULINEMIA; WEAKNESS; WEIGHT REDUCTION; BLOOD; COMBINATION DRUG THERAPY; DRUG INTERACTION; GENETICS; HEPACIVIRUS; HEPATITIS C; NEOPLASMS;

ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; NEOPLASMS; RNA, VIRAL;

EID: 84995804162     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13825     Document Type: Article

References (18)

1. AASLD/IDSA/IAS–USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org (accessed 20 September 2016).
2. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1–32.
3. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3: 333–40.
4. Torres HA, Mahale P, Blechacz B, et al. Effect of hepatitis C virus infection in patients with cancer: addressing a neglected population. J Natl Compr Canc Netw 2015; 13: 41–50.
5. Kemmer N, Neff GW. Managing chronic hepatitis C in the difficult-to-treat patient. Liver Int 2007; 27: 1297–310.
6. Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharm Ther 2016; 44: 856–65.
7. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharm Ther 2016; 43: 674–96.
8. Dick TB, Lindberg LS, Ramirez DD, et al. A clinician's guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology 2016; 63: 634–43.
9. Siederdissen CH, Maasoumy B, Marra F, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 2015; 62: 561–7.
10. th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016; 16: 606–17.
11. Torres HA, Chong PP, De Lima M, et al. Hepatitis C virus infection among hematopoietic cell transplant donors and recipients: American society for blood and marrow transplantation task force recommendations. Biol Blood Marrow Transplant 2015; 21: 1870–82.
12. Locasciulli A, Alberti A. Hepatitis C virus serum markers and liver disease in children with leukemia. Leuk Lymphoma 1995; 17: 245–9.
13. Torres HA, Kaseb A, Mahale P, et al. Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma 2014; 1: 109–14.
14. Majumdar A, Kitson MT, Roberts SK. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016; 43: 1276–92.
15. Deterding K, Honer Zu Siederdissen C, Port K, et al. Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 2015; 42: 899–901.
16. Kyvernitakis A, Mahale P, Popat UR, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant 2016; 22: 717–22.
17. Torres HA, McDonald GB. How we treat hepatitis C virus infection in patients with hematologic malignancies. Blood 2016; 128: 1449–57.
18. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiane Linfomi. Ann Oncol 2014; 25: 1404–10.